Sanofi is set to present new data from its diverse oncology pipeline at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6. A highlight of the presentations will be the results of a first-in-human study of SAR443579, an investigational trifunctional anti-CD123 NK cell engager, in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia. This study marks a significant step in Sanofi's research into potentially transformative therapies, including antibody drug conjugates, natural killer, and T-cell therapeutics.
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for SAR443579, aimed at facilitating the development and expediting the review of treatments for serious conditions with unmet medical needs. This designation underscores the potential of SAR443579 in addressing hematological malignancies.
Peter Adamson, Global Development Head of Oncology at Sanofi, emphasized the importance of the data presentation at ASCO, stating it supports the potential of this investigational approach for patients with difficult-to-treat cancers. Olivier Nataf, Global Head of Oncology, also highlighted the company's focus on exploring new opportunities and strategic partnerships to advance cancer treatment.
Sanofi's oncology pipeline has seen significant growth since 2019, with a focus on areas of high unmet needs. The company will also present studies on relapsed multiple myeloma, advanced solid tumors, and non-small cell lung cancer at ASCO, showcasing its commitment to advancing cancer research and treatment.
*These assets are currently under investigation and their safety and efficacy has not been fully evaluated by any health authority.
